These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8657614)

  • 1. [Protective properties of antibodies raised against conjugates of endotoxin core oligosaccharides with proteins].
    Jachymek W
    Postepy Hig Med Dosw; 1995; 49(1):171-8. PubMed ID: 8657614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in gram-negative bacterial infections.
    Lugowski C
    Acta Biochim Pol; 1995; 42(1):19-24. PubMed ID: 7653155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in anti-endotoxin-IgG antibody and endotoxaemia in three cases of gram-negative septic shock.
    Barclay GR; Scott BB; Wright IH; Rogers PN; Smith DG; Poxton IR
    Circ Shock; 1989 Oct; 29(2):93-106. PubMed ID: 2582583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human antiserum for prevention of the local shwartzman reaction and death from bacterial lipopolysaccharides.
    Ziegler EJ; Douglas H; Braude AI
    J Clin Invest; 1973 Dec; 52(12):3236-8. PubMed ID: 4584346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing and cross-reactive antibodies against enterobacterial lipopolysaccharide.
    Müller-Loennies S; Brade L; Brade H
    Int J Med Microbiol; 2007 Sep; 297(5):321-40. PubMed ID: 17544324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic strategies in cases of septicemia caused by gram-negative bacteria].
    Łukasiewicz J; Ługowski C
    Postepy Hig Med Dosw; 2003; 57(3):251-62. PubMed ID: 14524245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoprophylaxis and immunotherapy of Gram-negative infections in the immunocompromised host.
    Glauser MP; McCutchan JA; Ziegler E
    Clin Haematol; 1984 Oct; 13(3):549-55. PubMed ID: 6388931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Indications for passive immunotherapy in infectious diseases].
    Baumgartner JD
    Schweiz Med Wochenschr; 1987 Jan; 117(3):84-90. PubMed ID: 3823822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.
    Cross AS; Opal S; Cook P; Drabick J; Bhattacharjee A
    Vaccine; 2004 Feb; 22(7):812-7. PubMed ID: 15040932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological intervention in endotoxin shock.
    Ziegler EJ
    Prog Clin Biol Res; 1988; 272():319-25. PubMed ID: 3293079
    [No Abstract]   [Full Text] [Related]  

  • 13. Dissociation between Limulus neutralisation and in vivo protection in monoclonal antibodies directed against endotoxin core structures.
    McConnell JS; Appelmelk BJ; Cohen J
    Microb Pathog; 1990 Jul; 9(1):55-9. PubMed ID: 2077344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of monoclonal antibody therapy in the treatment of infectious disease.
    Chmel H
    Am J Hosp Pharm; 1990 Nov; 47(11 Suppl 3):S11-5. PubMed ID: 2275476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock.
    Quakyi EK; Frasch CE; Buller N; Tsai CM
    J Infect Dis; 1999 Sep; 180(3):747-54. PubMed ID: 10438363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage.
    Bochkov VN; Kadl A; Huber J; Gruber F; Binder BR; Leitinger N
    Nature; 2002 Sep; 419(6902):77-81. PubMed ID: 12214235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Generation and characterization of avian vitelline antibodies against lipopolysaccharide and lipid A. 2. Investigations of specificity of egg yolk antibodies (IgY) against endotoxin].
    Sasse M; Hlinak A
    Berl Munch Tierarztl Wochenschr; 1998 Apr; 111(4):127-33. PubMed ID: 9581346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective properties of a human IgG preparation rich in antibodies to a wide spectrum of lipopolysaccharides.
    Fomsgaard A; Galanos C
    APMIS; 1989 Dec; 97(12):1114-20. PubMed ID: 2611025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyxin B: an ode to an old antidote for endotoxic shock.
    Bhor VM; Thomas CJ; Surolia N; Surolia A
    Mol Biosyst; 2005 Sep; 1(3):213-22. PubMed ID: 16880985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The physicochemistry of endotoxins in relation to bioactivity.
    Gutsmann T; Schromm AB; Brandenburg K
    Int J Med Microbiol; 2007 Sep; 297(5):341-52. PubMed ID: 17452014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.